Literature DB >> 3926302

pH dependence of mitomycin C-induced cross-linking activity in EMT6 tumor cells.

K A Kennedy, J D McGurl, L Leondaridis, O Alabaster.   

Abstract

Mitomycin C (MC), a quinone-containing bioreductive alkylating agent, is cytotoxic to aerobic EMT6 tumor cells despite the fact that little bioactivation of MC occurs in EMT6 cell homogenates in the presence of O2. Because spontaneous activation of MC at acidic pH has been reported in chemical systems, aerobic EMT6 tumor cells were incubated in serum-free 2-(N-morpholino)ethanesulfonic acid or N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid buffer at pH 5.7, 6.4, and 7.5 and exposed to MC for 2 h. As the extracellular pH was lowered, MC-induced DNA-DNA cross-linking, as measured by alkaline elution techniques, was enhanced. This effect was dose dependent at the three pH values tested. Measurement of intracellular pH by flow cytometric analysis indicated that the decrease in extracellular pH was paralleled by a fall in intracellular pH. The alteration of the extracellular pH had no effect on the colony-forming ability of control cells. The survival of cells treated with MC, however, was decreased as the pH was lowered. These data suggest that the intracellular and/or the extracellular pH is an important determinant of MC activity in aerobic EMT6 tumor cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3926302

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 2.  Cellular pharmacology of quinone bioreductive alkylating agents.

Authors:  S Rockwell; A C Sartorelli; M Tomasz; K A Kennedy
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

3.  Enhancement of the efficacy of mitomycin C-mediated apoptosis in human colon cancer cells with RNAi-based thioredoxin reductase 1 deficiency.

Authors:  Preeyaporn Koedrith; Young Rok Seo
Journal:  Exp Ther Med       Date:  2011-06-30       Impact factor: 2.447

4.  Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures.

Authors:  W C Yen; T Schmittgen; J L Au
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

Review 5.  Are reduced quinones necessarily involved in the antitumour activity of quinone drugs?

Authors:  J Butler; B M Hoey
Journal:  Br J Cancer Suppl       Date:  1987-06

6.  In vitro cytotoxicity of pyrazine-2-diazohydroxide: specificity for hypoxic cells and effects of microsomal coincubation.

Authors:  J I Brodfüehrer; D J Moore; D C Melder; T J Wilke; G Powis
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

Review 7.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

Review 8.  DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C.

Authors:  D Ross; D Siegel; H Beall; A S Prakash; R T Mulcahy; N W Gibson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

9.  Dorzolamide synergizes the antitumor activity of mitomycin C against Ehrlich's carcinoma grown in mice: role of thioredoxin-interacting protein.

Authors:  Belal M Ali; Sawsan A Zaitone; Samia A Shouman; Yasser M Moustafa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-12       Impact factor: 3.000

Review 10.  NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.

Authors:  David Siegel; Chao Yan; David Ross
Journal:  Biochem Pharmacol       Date:  2011-12-24       Impact factor: 6.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.